Details werden geladen...
Half of new US-approved drugs remain unavailable to Japanese patients - Nikkei Asia
Many treatments have no domestic development plans due to regulatory, language barriers
Ähnliche Seiten
Japan release of new breast cancer, diabetes drugs delayed over pricing - Nikkei Asia
https://asia.nikkei.com/business/pharmaceuticals/japan-release-of-new-breast-cancer-diabetes-drugs-delayed-over-pricing3 Japanese shipbuilders to revive domestic production of LNG carriers - Nikkei Asia
https://asia.nikkei.com/business/transportation/3-japanese-shipbuilders-to-revive-domestic-production-of-lng-carriersTakaichi to stress Japanese investment in US in talks with Trump - Nikkei Asia
https://asia.nikkei.com/politics/international-relations/takaichi-to-stress-japanese-investment-in-us-in-talks-with-trumpJapan's Preferred Networks debuts AI priced less than half of OpenAI models - Nikkei Asia
https://asia.nikkei.com/business/technology/artificial-intelligence/japan-s-preferred-networks-debuts-ai-priced-less-than-half-of-openai-modelsFrom watches to sake, Japanese retailers try new tourist lures - Nikkei Asia
https://asia.nikkei.com/business/travel-leisure/from-watches-to-sake-japanese-retailers-try-new-tourist-lures